Carrier-antibody compositions and methods of making and using the same
Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
1. A lyophilized composition comprising nanoparticle complexes having an outside surface, said nanoparticle complexes comprising:
albumin;
paclitaxel; and
bevacizumab antibodies, each having a VEGF-binding portion and binding to the albumin and paclitaxel via non-covalent hydrophobic bonds;
said nanoparticle complexes being lyophilized, and wherein upon reconstitution with an aqueous solution an amount of the antibodies is arranged on the outside surface of the nanoparticle complexes and non-covalently bound to the albumin and paclitaxel, and the nanoparticle complexes are capable of binding to VEGF in vivo.
2. The lyophilized composition of claim 1 , wherein said complexes have an average size of less than 1 μm.
3. The lyophilized composition of claim 2 , wherein the average size is between about 130 nm and about 900 nm.
4. The lyophilized composition of claim 1 that is stable at about 20° C. to about 25° C. for at least 3 months.
5. The lyophilized composition of claim 1 , wherein each of the nanoparticle complexes comprises between about 400 and about 800 antibodies.
6. The lyophilized composition of claim 1 , wherein less than 0.01% of nanoparticle complexes have a size greater than 800 nm.
7. The lyophilized composition of claim 1 , wherein said nanoparticle complexes have an average size of about 160 nm.
8. The lyophilized composition of claim 1 , wherein the albumin is human serum albumin.
9. The lyophilized composition of claim 1 , wherein the nanoparticle complexes have a dissociation constant between about 1×10 −11 M and about 1×10 −9 M.
10. The lyophilized composition of claim 1 , wherein the lyophilized composition does not contain a bulking agent.
11. A method for treating a mammal having a cancer that expresses vascular endothelial growth factor (VEGF), said method comprising providing the lyophilized composition of claim 1 which was reconstituted in a pharmaceutically acceptable excipient to provide a reconstituted composition, and administering to the mammal a therapeutically effective amount of the reconstituted composition, thereby treating the cancer.
12. The method of claim 11 , wherein said mammal is a human.
13. The method of claim 11 , wherein said cancer is skin cancer, colon cancer, lung cancer, renal cancer, ovarian cancer, or glioblastoma multiforme.